BLAINJECTIONINJECTABLE
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
RIABNI (rituximab-arrx) by Amgen is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2020.
Drug data last refreshed 23h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIABNI is a CD20-directed monoclonal antibody biosimilar to rituximab developed by Amgen, approved in December 2020. It is indicated for B-cell malignancies and autoimmune conditions where CD20+ B cells are pathogenic. The drug works by binding to CD20 antigen on B cells, triggering cytolysis and immune-mediated cell death.
$0.003BPart D
PeakRIABNI is in peak commercial phase with modest Part D penetration ($3M), indicating opportunity for commercial expansion within a mature biosimilar segment.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RIABNI roles focus on competitive differentiation and market share capture in a crowded biosimilar space; career opportunities emphasize payer negotiations, competitive positioning, and field execution against entrenched rivals. This is a mature-market, execution-oriented product ideal for professionals seeking commercial skills in specialty pharma rather than product innovation.
Brand Manager (Oncology/Specialty)
Worked on RIABNI at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.